In the latest trading session, 2.6 million Outlook Therapeutics Inc (NASDAQ:OTLK) shares changed hands as the company’s beta touched 0.47. With the company’s most recent per share price at $2.23 changing hands around $0.18 or 9.02% at last look, the market valuation stands at $63.75M. OTLK’s current price is a discount, trading about -476.23% off its 52-week high of $12.85. The share price had its 52-week low at $0.87, which suggests the last value was 60.99% up since then. When we look at Outlook Therapeutics Inc’s average trading volume, we note the 10-day average is 7.24 million shares, with the 3-month average coming to 1.37 million.
Analysts gave the Outlook Therapeutics Inc (OTLK) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended OTLK as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Outlook Therapeutics Inc’s EPS for the current quarter is expected to be -0.9.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Instantly OTLK is in green as seen in intraday trades today. With action -55.57%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -71.64%, with the 5-day performance at -55.57% in the red. However, in the 30-day time frame, Outlook Therapeutics Inc (NASDAQ:OTLK) is -61.20% down. Looking at the short shares, we see there were 3.4 million shares sold at short interest cover period of 11.43 days.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Data shows that the Outlook Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -68.07% over the past 6 months, a 20.00% in annual growth rate that is considerably higher than the industry average of 17.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 52.49%. The 2024 estimates are for Outlook Therapeutics Inc earnings to decrease by -2.19%.
OTLK Dividends
Outlook Therapeutics Inc is expected to release its next quarterly earnings report in January.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 35.58% of Outlook Therapeutics Inc shares while 35.65% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 55.34%. There are 35.65% institutions holding the Outlook Therapeutics Inc stock share, with ROSALIND ADVISORS, INC. the top institutional holder. As of 2024-06-30, the company held 3.1534% of the shares, roughly 0.45 million OTLK shares worth $3.32 million.
CWM, LLC holds the second largest percentage of outstanding shares.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Extended Market Index Fund and Vanguard Total Stock Market Index Fund. With 283.49 shares estimated at $0.62 million under it, the former controlled 1.20% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 0.86% of the shares, roughly 204.51 shares worth around $0.44 million.
